Startups
Novoron Bioscience
Novoron Bioscience is a San Diego biotechnology company developing therapies for neurodegenerative disease and spinal cord injury using low-density lipoprotein receptor biology. Founded in 2014 by Travis Stiles and Shawn Gahr, it targets disease-related LRP1 signaling and protein interactions while seeking to preserve normal receptor functions. Its programs address tau and other protein propagation, neuronal repair and recovery after spinal cord injury. Novoron also develops human brain organoid screening tools, combining transcriptomic and AI-supported analyses to evaluate Alzheimer's disease drug candidates. Its leadership includes CEO and co-founder Travis Stiles, executive chairman David Weiner, COO and co-founder Shawn Gahr, drug discovery and translation specialists, and financial leadership. The company is supported by scientific and spinal cord injury advisory groups. Two Bear Capital led seed financings in 2021 and 2022. Its therapies remain investigational, and its Australian subsidiary Novoroo is pursuing preclinical NOVO-120 research for bladder dysfunction after spinal cord injury.
Founded 2014
Team
 Bryn MartinSpinal Cord Injury Advisory Council Member |
 David WeinerExecutive Chairman · Board Director |
 James WhisstockScientific Advisory Board Member |
 Jeff GoldbergScientific Advisory Board Member |
 Jennifer RauchScientific Advisory Board Member |
 Kurt BrundenScientific Advisory Board Member |
 Lawrence GoldsteinScientific Advisory Board Member |
 Linda JonesSpinal Cord Injury Advisory Council Member |
 Michael G. FehlingsSpinal Cord Injury Advisory Council Member |
 Miguel de los RiosScientific Advisory Board Member |
 Mike GoguenBoard Director |
 Rivka KreitmanScientific Advisory Board Member |
 Robert EastlackSpinal Cord Injury Advisory Council Member |
 Ryan McMillianChief Financial Officer, Financial Strategy and Business Development |
 Sarah BuschNon-Clinical Translation and Business Development |
 Shawn GahrCOO & Co-founder · Board Director |
 Travis StilesCEO & Co-founder · Chairman of the Board |
 William HoekstraDrug Discovery & Development |